|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
KR101736218B1
(ko)
|
2009-09-25 |
2017-05-16 |
오리존 지노믹스 에스.에이. |
라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
|
|
WO2011042217A1
(en)
|
2009-10-09 |
2011-04-14 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
|
WO2011106105A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
WO2011106106A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
JP5868948B2
(ja)
|
2010-04-19 |
2016-02-24 |
オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． |
リジン特異的脱メチル化酵素１阻害薬およびその使用
|
|
EP2598480B1
(en)
|
2010-07-29 |
2019-04-24 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
|
EP3375775A1
(en)
|
2010-07-29 |
2018-09-19 |
Oryzon Genomics, S.A. |
Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
|
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
JP6111195B2
(ja)
*
|
2011-08-09 |
2017-04-05 |
武田薬品工業株式会社 |
シクロプロパンアミン化合物
|
|
US9487512B2
(en)
|
2011-10-20 |
2016-11-08 |
Oryzon Genomics S.A. |
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
|
|
IL264982B
(en)
|
2011-10-20 |
2022-08-01 |
Oryzon Genomics Sa |
Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
|
|
KR102160320B1
(ko)
|
2012-10-02 |
2020-09-28 |
에피테라퓨틱스 에이피에스 |
히스톤 탈메틸효소의 저해제
|
|
CA2887598A1
(en)
|
2012-10-12 |
2014-04-17 |
Takeda Pharmaceutical Company Limited |
Cyclopropanamine compound and use thereof
|
|
EP2740474A1
(en)
*
|
2012-12-05 |
2014-06-11 |
Instituto Europeo di Oncologia S.r.l. |
Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
|
|
ES2670864T3
(es)
|
2013-02-27 |
2018-06-01 |
Gilead Sciences, Inc. |
Inhibidores de histonas desmetilasas
|
|
US9918983B2
(en)
*
|
2013-05-30 |
2018-03-20 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells
|
|
US9771348B2
(en)
*
|
2013-07-25 |
2017-09-26 |
Dong-A St Co., Ltd |
Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate
|
|
CN105592888A
(zh)
|
2013-08-06 |
2016-05-18 |
伊美格生物科学公司 |
用于治疗疾病的kdm1a抑制剂
|
|
TW201613860A
(en)
|
2014-02-13 |
2016-04-16 |
Incyte Corp |
Cyclopropylamines as LSD1 inhibitors
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
CN106488915B
(zh)
|
2014-02-13 |
2020-10-02 |
因赛特公司 |
作为lsd1抑制剂的环丙胺
|
|
SG10201806849WA
(en)
*
|
2014-02-13 |
2018-09-27 |
Incyte Corp |
Cyclopropylamines as lsd1 inhibitors
|
|
CN104042616B
(zh)
*
|
2014-02-20 |
2016-08-24 |
复旦大学附属眼耳鼻喉科医院 |
赖氨酸特异性去甲基化酶1抑制剂的应用
|
|
TWI669291B
(zh)
*
|
2014-04-11 |
2019-08-21 |
日商武田藥品工業股份有限公司 |
環丙胺化合物及其用途
|
|
RS62874B1
(sr)
|
2014-05-01 |
2022-02-28 |
Celgene Quanticel Research Inc |
Inhibitori lizin specifične demetilaze-1
|
|
US9695168B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
|
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
|
US9695167B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
|
|
TW201613925A
(en)
|
2014-07-10 |
2016-04-16 |
Incyte Corp |
Imidazopyrazines as LSD1 inhibitors
|
|
TW201625536A
(zh)
|
2014-08-27 |
2016-07-16 |
艾比療法公司 |
抑制組蛋白去甲基酶之化合物及方法
|
|
WO2016055935A1
(en)
*
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
|
EA039196B1
(ru)
*
|
2014-10-08 |
2021-12-16 |
Инсайт Корпорейшн |
Циклопропиламины в качестве ингибиторов lsd1
|
|
CN107438593B
(zh)
*
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
|
EP4559902A3
(en)
|
2015-02-12 |
2025-08-20 |
Imago Biosciences Inc. |
Kdm1a inhibitors for the treatment of disease
|
|
US9944647B2
(en)
|
2015-04-03 |
2018-04-17 |
Incyte Corporation |
Heterocyclic compounds as LSD1 inhibitors
|
|
WO2016172496A1
(en)
|
2015-04-23 |
2016-10-27 |
Constellation Pharmaceuticals, Inc. |
Lsd1 inhibitors and uses thereof
|
|
EP3090998A1
(en)
|
2015-05-06 |
2016-11-09 |
F. Hoffmann-La Roche AG |
Solid forms
|
|
MX2017015922A
(es)
|
2015-06-12 |
2018-12-11 |
Oryzon Genomics Sa |
Biomarcadores asociados con inhibidores de lsd1 y usos de los mismos.
|
|
WO2017013061A1
(en)
|
2015-07-17 |
2017-01-26 |
Oryzon Genomics, S.A. |
Biomarkers associated with lsd1 inhibitors and uses thereof
|
|
UA126277C2
(uk)
*
|
2015-08-12 |
2022-09-14 |
Інсайт Корпорейшн |
Солі інгібітору lsd1
|
|
JP2018526371A
(ja)
|
2015-08-27 |
2018-09-13 |
ジェネンテック， インコーポレイテッド |
治療化合物及びその使用方法
|
|
US10059668B2
(en)
|
2015-11-05 |
2018-08-28 |
Mirati Therapeutics, Inc. |
LSD1 inhibitors
|
|
US10899732B2
(en)
|
2015-11-25 |
2021-01-26 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
WO2017097865A1
(en)
*
|
2015-12-07 |
2017-06-15 |
Istituto Europeo Di Oncologia |
Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
|
|
SG11201805645QA
(en)
*
|
2015-12-29 |
2018-07-30 |
Mirati Therapeutics Inc |
Lsd1 inhibitors
|
|
EP3397756B1
(en)
|
2015-12-30 |
2023-03-08 |
Novartis AG |
Immune effector cell therapies with enhanced efficacy
|
|
EP3429571B1
(en)
|
2016-03-15 |
2025-10-08 |
Oryzon Genomics, S.A. |
Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
|
|
KR102646126B1
(ko)
|
2016-03-15 |
2024-03-11 |
오리존 지노믹스 에스.에이. |
혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
|
|
JP2019512546A
(ja)
*
|
2016-03-16 |
2019-05-16 |
オリゾン・ゲノミクス・ソシエダッド・アノニマ |
Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
|
|
CN107200706A
(zh)
*
|
2016-03-16 |
2017-09-26 |
中国科学院上海药物研究所 |
一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
|
|
EP3436432B1
(en)
|
2016-03-30 |
2021-01-27 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
BR112018071585B1
(pt)
|
2016-04-22 |
2024-01-02 |
Incyte Corporation |
Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas
|
|
CN107459476B
(zh)
*
|
2016-06-03 |
2022-06-24 |
中国科学院上海药物研究所 |
反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
|
|
CA2988220C
(en)
|
2016-06-10 |
2021-03-02 |
Oryzon Genomics, S.A. |
Methods of treating multiple sclerosis
|
|
WO2018020366A1
(en)
|
2016-07-26 |
2018-02-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Crystalline (r)-mandelate salt of (1r,2s)-2-phenylcyclopropylamine
|
|
SG10201610038SA
(en)
*
|
2016-07-29 |
2017-12-28 |
Apple Inc |
Systems and methods for management of asymmetrical multi-tapped battery packs
|
|
US11390590B2
(en)
|
2016-08-16 |
2022-07-19 |
Imago Biosciences, Inc. |
Methods and processes for the preparation of KDM1A inhibitors
|
|
CN110072855A
(zh)
|
2016-10-17 |
2019-07-30 |
基因泰克公司 |
治疗性化合物及其使用方法
|
|
WO2018083138A1
(en)
|
2016-11-03 |
2018-05-11 |
Oryzon Genomics, S.A. |
Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
|
|
EP3535420A1
(en)
|
2016-11-03 |
2019-09-11 |
Oryzon Genomics, S.A. |
Biomarkers for determining responsiveness to lsd1 inhibitors
|
|
EP3551178A1
(en)
|
2016-12-09 |
2019-10-16 |
Constellation Pharmaceuticals, Inc. |
Markers for personalized cancer treatment with lsd1 inhibitors
|
|
JP7217712B2
(ja)
*
|
2017-01-24 |
2023-02-03 |
シーエスピーシー ジョォンチィ ファーマシューティカル テクノロジー （シージアジョァン）カンパニー，リミテッド |
Ｌｓｄ１阻害剤、その製造方法及び応用
|
|
EP3601273B1
(en)
|
2017-03-24 |
2021-12-01 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
|
WO2018197583A1
(en)
|
2017-04-26 |
2018-11-01 |
Istituto Europeo Di Oncologia |
Use of a combinational therapy of lsd1 inhibitors with p21 activators in the treatment of cancer
|
|
EP3632443B1
(en)
|
2017-05-26 |
2023-06-07 |
Taiho Pharmaceutical Co., Ltd. |
Anti-tumor effect potentiator using a biphenyl compound
|
|
KR102361918B1
(ko)
|
2017-05-26 |
2022-02-14 |
다이호야쿠힌고교 가부시키가이샤 |
신규 비페닐 화합물 또는 그의 염
|
|
MA50518A
(fr)
|
2017-05-31 |
2020-09-09 |
Taiho Pharmaceutical Co Ltd |
Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1
|
|
KR20180134675A
(ko)
*
|
2017-06-09 |
2018-12-19 |
한미약품 주식회사 |
시클로프로필아민 유도체 화합물 및 이의 용도
|
|
JP2020152641A
(ja)
*
|
2017-07-07 |
2020-09-24 |
国立研究開発法人理化学研究所 |
リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
|
|
BR112020000827A2
(pt)
|
2017-08-03 |
2020-07-21 |
Oryzon Genomics, S.A. |
métodos de tratamento de alterações de comportamento
|
|
TWI794294B
(zh)
|
2017-09-13 |
2023-03-01 |
南韓商韓美藥品股份有限公司 |
吡唑衍生化合物及其用途
|
|
WO2019068326A1
(en)
|
2017-10-05 |
2019-04-11 |
Université D'aix-Marseille |
INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
|
|
KR20190040783A
(ko)
|
2017-10-11 |
2019-04-19 |
한미약품 주식회사 |
라이신 특이적 데메틸라제-1 억제제로서의 피라졸 유도체
|
|
KR20190040763A
(ko)
|
2017-10-11 |
2019-04-19 |
한미약품 주식회사 |
피라졸로피리딘 유도체 화합물 및 이의 용도
|
|
US11685782B2
(en)
|
2017-10-23 |
2023-06-27 |
Children's Medical Center Corporation |
Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
|
|
WO2019109095A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Beth Israel Deaconess Medical Center, Inc. |
Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
|
|
CN108107199B
(zh)
*
|
2017-12-21 |
2019-02-12 |
广州市进德生物科技有限公司 |
一种酶化学发光法测定尿酸的检测试剂盒
|
|
US11028075B2
(en)
|
2018-02-26 |
2021-06-08 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
CN111936494A
(zh)
|
2018-03-30 |
2020-11-13 |
豪夫迈·罗氏有限公司 |
作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
|
|
AU2019265022B2
(en)
|
2018-05-11 |
2024-08-15 |
Imago Biosciences, Inc. |
KDM1A inhibitors for the treatment of disease
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
AU2019303777B2
(en)
*
|
2018-07-20 |
2023-01-19 |
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. |
Salt of LSD1 inhibitor and a polymorph thereof
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
WO2020052647A1
(zh)
*
|
2018-09-13 |
2020-03-19 |
南京明德新药研发有限公司 |
作为lsd1抑制剂的杂螺环类化合物及其应用
|
|
CN112689638B
(zh)
*
|
2018-09-13 |
2022-11-08 |
南昌弘益药业有限公司 |
作为lsd1抑制剂的环丙胺类化合物及其应用
|
|
EP3890715A4
(en)
*
|
2018-12-04 |
2023-03-29 |
The Board Of Regents Of The University Of Texas System |
ANTI-ADENOMATOUS POLYPOSIS COLI (APC) THERAPEUTICS FOR THE TREATMENT OF CANCER
|
|
WO2020138398A1
(ja)
*
|
2018-12-28 |
2020-07-02 |
国立研究開発法人理化学研究所 |
リジン特異的脱メチル化酵素１を阻害する新規化合物、その製造方法及びその用途
|
|
JP7532386B2
(ja)
|
2019-02-01 |
2024-08-13 |
ハンミ ファーマシューティカルズ カンパニー リミテッド |
イミダゾピリジン誘導体化合物及びその用途
|
|
CN113365996B
(zh)
*
|
2019-02-01 |
2024-09-03 |
韩美药品株式会社 |
咪唑吡啶衍生化合物以及药物组成物
|
|
PH12021552251A1
(en)
|
2019-03-20 |
2022-07-25 |
Oryzon Genomics Sa |
Methods of treating borderline personality disorder
|
|
JP7535797B2
(ja)
|
2019-03-20 |
2024-08-19 |
オリソン ヘノミクス，ソシエダ アノニマ |
化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法
|
|
WO2021004610A1
(en)
|
2019-07-05 |
2021-01-14 |
Oryzon Genomics, S.A. |
Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
|
|
WO2021058024A1
(zh)
*
|
2019-09-29 |
2021-04-01 |
南京明德新药研发有限公司 |
Lsd1抑制剂
|
|
JP7588160B2
(ja)
*
|
2020-05-28 |
2024-11-21 |
ナイキ イノベイト シーブイ |
流体移動制御および調整可能足支持圧力を含む足支持システム
|
|
EP3964204A1
(en)
|
2020-09-08 |
2022-03-09 |
Université d'Aix-Marseille |
Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
|
|
WO2022171044A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南昌弘益药业有限公司 |
一种氧氮杂螺环化合物、其盐型及其晶型
|
|
BR112023020554A2
(pt)
|
2021-04-08 |
2023-12-05 |
Oryzon Genomics Sa |
Combinações de inibidores de lsd1 para o tratamento de cânceres mieloides
|
|
WO2022267495A1
(zh)
*
|
2021-06-22 |
2022-12-29 |
南昌弘益药业有限公司 |
含氮氧杂螺环类化合物及其应用
|
|
CN113512031B
(zh)
*
|
2021-07-01 |
2024-01-30 |
都创(上海)医药开发有限公司 |
一种lsd1酶抑制剂tak-418中间体化合物制备方法
|
|
GB202115017D0
(en)
|
2021-10-20 |
2021-12-01 |
Univ London Queen Mary |
Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
|
|
US20240418723A1
(en)
|
2021-10-20 |
2024-12-19 |
Queen Mary University Of London |
Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
|
|
CN119497613A
(zh)
|
2022-05-09 |
2025-02-21 |
奥莱松基因组股份有限公司 |
使用lsd1抑制剂治疗nf1-突变肿瘤的方法
|
|
JP2025516647A
(ja)
|
2022-05-09 |
2025-05-30 |
オリゾン・ゲノミクス・ソシエダッド・アノニマ |
Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
|
|
EP4622635A1
(en)
|
2022-11-24 |
2025-10-01 |
Oryzon Genomics, S.A. |
Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
CN117164465B
(zh)
*
|
2023-09-04 |
2025-07-01 |
郑州大学 |
一种苯基环丙胺类化合物及其制备方法和应用
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|